Do analysts prefer CASI or ADIL?

Adial Pharmaceuticals has a consensus target price of $8.33, suggesting a potential upside of 153.29%. Given Adial Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Adial Pharmaceuticals is more favorable than CASI Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CASI Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Adial Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Do analysts prefer CASI or QNRX?

Quoin Pharmaceuticals has a consensus target price of $17.00, suggesting a potential upside of 309.64%. Given Quoin Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Quoin Pharmaceuticals is more favorable than CASI Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CASI Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Quoin Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Does the media refer more to CASI or QNRX?

In the previous week, Quoin Pharmaceuticals had 3 more articles in the media than CASI Pharmaceuticals. MarketBeat recorded 4 mentions for Quoin Pharmaceuticals and 1 mentions for CASI Pharmaceuticals. Quoin Pharmaceuticals' average media sentiment score of 0.76 beat CASI Pharmaceuticals' score of 0.00 indicating that Quoin Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CASI Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Quoin Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend CALC or CASI?

CalciMedica presently has a consensus target price of $50.00, suggesting a potential upside of 4,364.29%. Given CalciMedica's stronger consensus rating and higher probable upside, equities analysts clearly believe CalciMedica is more favorable than CASI Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CalciMedica 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20 CASI Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is CALC or CASI more profitable?

CalciMedica has a net margin of 0.00% compared to CASI Pharmaceuticals' net margin of -183.93%. Company Net Margins Return on Equity Return on Assets CalciMedica N/A N/A -155.24% CASI Pharmaceuticals -183.93% N/A -131.54%

Do analysts prefer CASI or MBRX?

Moleculin Biotech has a consensus target price of $3.00, suggesting a potential upside of 589.34%. Given Moleculin Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Moleculin Biotech is more favorable than CASI Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CASI Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Moleculin Biotech 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Does the media refer more to CASI or MBRX?

In the previous week, Moleculin Biotech had 1 more articles in the media than CASI Pharmaceuticals. MarketBeat recorded 2 mentions for Moleculin Biotech and 1 mentions for CASI Pharmaceuticals. Moleculin Biotech's average media sentiment score of 0.60 beat CASI Pharmaceuticals' score of 0.00 indicating that Moleculin Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CASI Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Moleculin Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend OBSV or CASI?

Given ObsEva's higher probable upside, equities analysts plainly believe ObsEva is more favorable than CASI Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ObsEva 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 CASI Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

CASI Pharmaceuticals (CASI) Competitors

$0.21 0.00 (0.00%)

As of 10/13/2026

Compare

CASI vs. ADIL, QNRX, CALC, MBRX, and OBSV

Should you buy CASI Pharmaceuticals stock or one of its competitors? CASI Pharmaceuticals's main competitors and comparable companies include Adial Pharmaceuticals (ADIL), Quoin Pharmaceuticals (QNRX), CalciMedica (CALC), Moleculin Biotech (MBRX), and ObsEva (OBSV). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does CASI Pharmaceuticals compare to Adial Pharmaceuticals?

CASI Pharmaceuticals (NASDAQ:CASI) and Adial Pharmaceuticals (NASDAQ:ADIL) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, media sentiment, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation.

22.2% of CASI Pharmaceuticals shares are held by institutional investors. Comparatively, 16.4% of Adial Pharmaceuticals shares are held by institutional investors. 21.2% of CASI Pharmaceuticals shares are held by company insiders. Comparatively, 8.0% of Adial Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Adial Pharmaceuticals has lower revenue, but higher earnings than CASI Pharmaceuticals. Adial Pharmaceuticals is trading at a lower price-to-earnings ratio than CASI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CASI Pharmaceuticals	$26.85M	0.10	-$39.26M	-$3.01	N/A
Adial Pharmaceuticals	N/A	N/A	-$7.98M	-$14.73	N/A

Adial Pharmaceuticals has a net margin of 0.00% compared to CASI Pharmaceuticals' net margin of -183.93%. CASI Pharmaceuticals' return on equity of 0.00% beat Adial Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CASI Pharmaceuticals	-183.93%	N/A	-131.54%
Adial Pharmaceuticals	N/A	-203.87%	-512.41%

CASI Pharmaceuticals has a beta of 0.91, meaning that its stock price is 9% less volatile than the broader market. Comparatively, Adial Pharmaceuticals has a beta of 1.5, meaning that its stock price is 50% more volatile than the broader market.

Adial Pharmaceuticals has a consensus target price of $8.33, suggesting a potential upside of 153.29%. Given Adial Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Adial Pharmaceuticals is more favorable than CASI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CASI Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Adial Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Adial Pharmaceuticals had 1 more articles in the media than CASI Pharmaceuticals. MarketBeat recorded 1 mentions for Adial Pharmaceuticals and 0 mentions for CASI Pharmaceuticals. Adial Pharmaceuticals' average media sentiment score of 1.82 beat CASI Pharmaceuticals' score of 0.00 indicating that Adial Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
CASI Pharmaceuticals	Neutral
Adial Pharmaceuticals	Very Positive

Summary

Adial Pharmaceuticals beats CASI Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does CASI Pharmaceuticals compare to Quoin Pharmaceuticals?

CASI Pharmaceuticals (NASDAQ:CASI) and Quoin Pharmaceuticals (NASDAQ:QNRX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership, media sentiment and valuation.

22.2% of CASI Pharmaceuticals shares are owned by institutional investors. Comparatively, 8.6% of Quoin Pharmaceuticals shares are owned by institutional investors. 21.2% of CASI Pharmaceuticals shares are owned by insiders. Comparatively, 7.5% of Quoin Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Quoin Pharmaceuticals has a consensus target price of $17.00, suggesting a potential upside of 309.64%. Given Quoin Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Quoin Pharmaceuticals is more favorable than CASI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CASI Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Quoin Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Quoin Pharmaceuticals had 3 more articles in the media than CASI Pharmaceuticals. MarketBeat recorded 4 mentions for Quoin Pharmaceuticals and 1 mentions for CASI Pharmaceuticals. Quoin Pharmaceuticals' average media sentiment score of 0.76 beat CASI Pharmaceuticals' score of 0.00 indicating that Quoin Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CASI Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Quoin Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CASI Pharmaceuticals has a beta of 0.91, meaning that its share price is 9% less volatile than the broader market. Comparatively, Quoin Pharmaceuticals has a beta of 1.56, meaning that its share price is 56% more volatile than the broader market.

Quoin Pharmaceuticals has lower revenue, but higher earnings than CASI Pharmaceuticals. Quoin Pharmaceuticals is trading at a lower price-to-earnings ratio than CASI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CASI Pharmaceuticals	$26.85M	0.10	-$39.26M	-$3.01	N/A
Quoin Pharmaceuticals	N/A	N/A	-$15.81M	-$25.18	N/A

Quoin Pharmaceuticals has a net margin of 0.00% compared to CASI Pharmaceuticals' net margin of -183.93%. CASI Pharmaceuticals' return on equity of 0.00% beat Quoin Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CASI Pharmaceuticals	-183.93%	N/A	-131.54%
Quoin Pharmaceuticals	N/A	-489.57%	-221.17%

Summary

Quoin Pharmaceuticals beats CASI Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does CASI Pharmaceuticals compare to CalciMedica?

CalciMedica (NASDAQ:CALC) and CASI Pharmaceuticals (NASDAQ:CASI) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability.

CalciMedica presently has a consensus target price of $50.00, suggesting a potential upside of 4,364.29%. Given CalciMedica's stronger consensus rating and higher probable upside, equities analysts clearly believe CalciMedica is more favorable than CASI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CalciMedica	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
CASI Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

CalciMedica has a net margin of 0.00% compared to CASI Pharmaceuticals' net margin of -183.93%.

Company	Net Margins	Return on Equity	Return on Assets
CalciMedica	N/A	N/A	-155.24%
CASI Pharmaceuticals	-183.93%	N/A	-131.54%

22.2% of CASI Pharmaceuticals shares are held by institutional investors. 28.3% of CalciMedica shares are held by insiders. Comparatively, 21.2% of CASI Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

CalciMedica has higher earnings, but lower revenue than CASI Pharmaceuticals. CalciMedica is trading at a lower price-to-earnings ratio than CASI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CalciMedica	N/A	N/A	-$29.56M	-$6.80	N/A
CASI Pharmaceuticals	$26.85M	0.10	-$39.26M	-$3.01	N/A

CalciMedica has a beta of 0.76, suggesting that its share price is 24% less volatile than the broader market. Comparatively, CASI Pharmaceuticals has a beta of 0.91, suggesting that its share price is 9% less volatile than the broader market.

In the previous week, CalciMedica had 2 more articles in the media than CASI Pharmaceuticals. MarketBeat recorded 2 mentions for CalciMedica and 0 mentions for CASI Pharmaceuticals. CalciMedica's average media sentiment score of 0.61 beat CASI Pharmaceuticals' score of 0.00 indicating that CalciMedica is being referred to more favorably in the media.

Company	Overall Sentiment
CalciMedica	Positive
CASI Pharmaceuticals	Neutral

Summary

CalciMedica beats CASI Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does CASI Pharmaceuticals compare to Moleculin Biotech?

CASI Pharmaceuticals (NASDAQ:CASI) and Moleculin Biotech (NASDAQ:MBRX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, risk, institutional ownership and media sentiment.

Moleculin Biotech has a net margin of 0.00% compared to CASI Pharmaceuticals' net margin of -183.93%. CASI Pharmaceuticals' return on equity of 0.00% beat Moleculin Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CASI Pharmaceuticals	-183.93%	N/A	-131.54%
Moleculin Biotech	N/A	-143.51%	-24.53%

Moleculin Biotech has lower revenue, but higher earnings than CASI Pharmaceuticals. CASI Pharmaceuticals is trading at a lower price-to-earnings ratio than Moleculin Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CASI Pharmaceuticals	$26.85M	0.10	-$39.26M	-$3.01	N/A
Moleculin Biotech	N/A	N/A	-$33.56M	-$7.13	N/A

In the previous week, Moleculin Biotech had 1 more articles in the media than CASI Pharmaceuticals. MarketBeat recorded 2 mentions for Moleculin Biotech and 1 mentions for CASI Pharmaceuticals. Moleculin Biotech's average media sentiment score of 0.60 beat CASI Pharmaceuticals' score of 0.00 indicating that Moleculin Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CASI Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Moleculin Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CASI Pharmaceuticals has a beta of 0.91, meaning that its stock price is 9% less volatile than the broader market. Comparatively, Moleculin Biotech has a beta of 2, meaning that its stock price is 100% more volatile than the broader market.

Moleculin Biotech has a consensus target price of $3.00, suggesting a potential upside of 589.34%. Given Moleculin Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Moleculin Biotech is more favorable than CASI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CASI Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Moleculin Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

22.2% of CASI Pharmaceuticals shares are owned by institutional investors. Comparatively, 15.5% of Moleculin Biotech shares are owned by institutional investors. 21.2% of CASI Pharmaceuticals shares are owned by insiders. Comparatively, 18.0% of Moleculin Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Moleculin Biotech beats CASI Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does CASI Pharmaceuticals compare to ObsEva?

ObsEva (NASDAQ:OBSV) and CASI Pharmaceuticals (NASDAQ:CASI) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations, media sentiment and dividends.

ObsEva has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market. Comparatively, CASI Pharmaceuticals has a beta of 0.91, suggesting that its stock price is 9% less volatile than the broader market.

ObsEva has a net margin of 0.00% compared to CASI Pharmaceuticals' net margin of -183.93%. CASI Pharmaceuticals' return on equity of 0.00% beat ObsEva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ObsEva	N/A	-416.36%	-92.01%
CASI Pharmaceuticals	-183.93%	N/A	-131.54%

CASI Pharmaceuticals has higher revenue and earnings than ObsEva. CASI Pharmaceuticals is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ObsEva	N/A	N/A	-$58.38M	-$0.92	N/A
CASI Pharmaceuticals	$26.85M	0.10	-$39.26M	-$3.01	N/A

17.5% of ObsEva shares are owned by institutional investors. Comparatively, 22.2% of CASI Pharmaceuticals shares are owned by institutional investors. 14.4% of ObsEva shares are owned by insiders. Comparatively, 21.2% of CASI Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, CASI Pharmaceuticals had 1 more articles in the media than ObsEva. MarketBeat recorded 1 mentions for CASI Pharmaceuticals and 0 mentions for ObsEva. ObsEva's average media sentiment score of 0.00 equaled CASI Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
ObsEva	Neutral
CASI Pharmaceuticals	Neutral

Given ObsEva's higher probable upside, equities analysts plainly believe ObsEva is more favorable than CASI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ObsEva	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
CASI Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

CASI Pharmaceuticals beats ObsEva on 8 of the 13 factors compared between the two stocks.

Get CASI Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CASI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CASI vs. The Competition

Export

Metric	CASI Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.55M	$12.42B	$7.27B	$12.97B
Dividend Yield	N/A	2.63%	2.51%	22.89%
P/E Ratio	-0.07	807.81	275.40	25.37
Price / Sales	0.10	748.45	562.29	78.82
Price / Cash	N/A	86.65	77.16	53.04
Price / Book	1.73	9.21	10.55	5.95
Net Income	-$39.26M	$2.84B	$3.50B	$380.75M
7 Day Performance	N/A	-4.00%	-3.92%	-3.96%
1 Month Performance	N/A	-8.07%	-8.30%	-6.81%
1 Year Performance	-88.54%	-5.86%	2.35%	-4.58%

CASI Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CASI CASI Pharmaceuticals	N/A	$0.21 flat	N/A	N/A	$2.55M	$26.85M	N/A	180
ADIL Adial Pharmaceuticals	2.7255 of 5 stars	$3.29 -6.0%	$8.33 +153.3%	-64.4%	$9.19M	N/A	N/A	6	Positive News Analyst Downgrade
QNRX Quoin Pharmaceuticals	4.1824 of 5 stars	$4.15 -4.8%	$17.00 +309.6%	-72.1%	$8.76M	N/A	N/A	6	News Coverage Analyst Forecast Short Interest Decrease Gap Up
CALC CalciMedica	3.5847 of 5 stars	$1.12 -7.1%	$50.00 +4,364.3%	-93.1%	$8.23M	N/A	N/A	15
MBRX Moleculin Biotech	3.6938 of 5 stars	$0.44 +5.1%	$3.00 +589.3%	-96.3%	$8.06M	N/A	N/A	17	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CASI) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CASI Pharmaceuticals (CASI) Competitors

CASI vs. ADIL, QNRX, CALC, MBRX, and OBSV

How does CASI Pharmaceuticals compare to Adial Pharmaceuticals?

Summary

How does CASI Pharmaceuticals compare to Quoin Pharmaceuticals?

Summary

How does CASI Pharmaceuticals compare to CalciMedica?

Summary

How does CASI Pharmaceuticals compare to Moleculin Biotech?

Summary

How does CASI Pharmaceuticals compare to ObsEva?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CASI vs. The Competition

CASI Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CASI Pharmaceuticals (CASI) Competitors

CASI vs. ADIL, QNRX, CALC, MBRX, and OBSV

How does CASI Pharmaceuticals compare to Adial Pharmaceuticals?

Do institutionals and insiders have more ownership in CASI or ADIL?

Which has stronger earnings & valuation, CASI or ADIL?

Is CASI or ADIL more profitable?

Which has more volatility & risk, CASI or ADIL?

Do analysts prefer CASI or ADIL?

Does the media favor CASI or ADIL?

Summary

How does CASI Pharmaceuticals compare to Quoin Pharmaceuticals?

Do institutionals & insiders hold more shares of CASI or QNRX?

Do analysts prefer CASI or QNRX?

Does the media refer more to CASI or QNRX?

Which has more volatility and risk, CASI or QNRX?

Which has better valuation and earnings, CASI or QNRX?

Is CASI or QNRX more profitable?

Summary

How does CASI Pharmaceuticals compare to CalciMedica?

Do analysts recommend CALC or CASI?

Is CALC or CASI more profitable?

Do insiders & institutionals have more ownership in CALC or CASI?

Which has preferable valuation & earnings, CALC or CASI?

Which has more volatility & risk, CALC or CASI?

Does the media refer more to CALC or CASI?

Summary

How does CASI Pharmaceuticals compare to Moleculin Biotech?

Is CASI or MBRX more profitable?

Which has preferable valuation & earnings, CASI or MBRX?

Does the media refer more to CASI or MBRX?

Which has more risk & volatility, CASI or MBRX?

Do analysts prefer CASI or MBRX?

Do institutionals & insiders hold more shares of CASI or MBRX?

Summary

How does CASI Pharmaceuticals compare to ObsEva?

Which has more risk & volatility, OBSV or CASI?

Is OBSV or CASI more profitable?

Which has better earnings and valuation, OBSV or CASI?

Do insiders and institutionals have more ownership in OBSV or CASI?

Does the media prefer OBSV or CASI?

Do analysts recommend OBSV or CASI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CASI vs. The Competition

CASI Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools